BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 27.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 217,740 shares of the biotechnology company's stock after purchasing an additional 46,650 shares during the period. Schonfeld Strategic Advisors LLC owned about 0.11% of BioCryst Pharmaceuticals worth $1,637,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Venturi Wealth Management LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $48,000. KBC Group NV raised its holdings in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 4,537 shares in the last quarter. Raymond James Financial Inc. bought a new position in BioCryst Pharmaceuticals during the 4th quarter valued at $80,000. Finally, Syon Capital LLC bought a new position in BioCryst Pharmaceuticals during the 4th quarter valued at $99,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX traded up $0.41 during midday trading on Monday, reaching $10.38. 1,284,197 shares of the company traded hands, compared to its average volume of 2,983,185. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -16.96 and a beta of 1.08. The company has a fifty day moving average price of $7.87 and a 200 day moving average price of $7.89. BioCryst Pharmaceuticals, Inc. has a twelve month low of $5.34 and a twelve month high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The business's revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.28 EPS. On average, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. JMP Securities reissued a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Royal Bank of Canada restated an "outperform" rating and set a $13.00 price objective (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price on the stock. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Finally, StockNews.com raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.